Primary Care Diabetes Prescriptions Cost UK Over £2 Million a Day
Prescriptions to manage diabetes in primary care in the UK cost the NHS an average of £2.2 million ($3.7 m) every day in 2013-14, according to a report from the Health and Social Care Information Centre (HSCIC).
Prescriptions to manage diabetes in primary care in the UK cost the NHS an average of £2.2 million ($3.7 m) every day in 2013-14, according to a report from the Health and Social Care Information Centre (HSCIC).
The report, Prescribing for Diabetes, also shows the Net Ingredient Cost (NIC) for managing diabetes was £803.1 million ($1,347 m) in 2013–14. This is a 5.1 per cent increase from £764.1 million in 2012–13 (£2.1 million per day on average) and a 56.3 per cent increase on £2005-06 (£1.4 million per day on average).
Almost 10 per cent (9.5 per cent) of the NHS’s total primary care drugs bill was spent on managing diabetes, revealing a continuous annual rise from 6.6 per cent in 2005–06.
THe HSCIC report shows that in primary care in 2013-14:
- There were 45.1 million prescription items for managing diabetes, an average of 123,610 items per day.
- Insulin items can be prescribed for both type 1 and type 2 diabetes and accounted for about one in seven items prescribed for diabetes.
- Seven out of ten diabetes prescription items were for anti diabetic drugs, which are prescribed only for type 2 diabetes.
- Diagnositic and monitoring devices made up the remainder of diabetes items prescribed and the majority of these were blood glucose testing strips.
- Costs of all three categories of diabetes drugs have increased from 2005-06 but in particular insulin items where the rise in spending was 11.6 per cent higher than the rise in items prescribed.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.